Select Your Region
Americas
Europa
Afrika
Weltweit
Teilnehmende, medizinische Einrichtungen finden und deren aktuellen Studienstatus anzeigen
Teilnehmende, medizinische Einrichtungen finden
-
Startseite
-
Suche nach klinischen Studien
- Details zu klinischen Studien
Eine Verlängerungsstudie zur Sicherheit und Wirksamkeit von Pertuzumab bei Patient*innen mit soliden Tumoren, die zuvor an einer von Hoffmann-La Roche gesponserten Pertuzumab-Studie teilgenommen hatten
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Krebs Solide Tumore
Basisinformationen
Sponsor
Hoffmann-La Roche
Phase
Phase 3
Studien-ID
NCT02320435, MO29406, 2014-002048-42,2023-505102-42-00
Condition
Solid Tumor
Official Title
A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
Einschlusskriterien
All
≥18 Years
No
Inclusion Criteria
- Informed consent
- Prior eligibility for, and receiving pertuzumab as an investigational medicinal product in, a Roche-sponsored study (either as a single agent or in combination with other anti-cancer drugs used in the Parent study) at the time of the Parent study closure
- Investigator's opinion that the patient continues to benefit from treatment
Exclusion Criteria
- Meets any of the exclusion criteria of the Parent protocol at the time the patient is considered for entry in the extension study
- Evidence of disease progression assessed according to Parent protocol before enrollment in to the extension study
- Permanent discontinuation of pertuzumab for any reason during the Parent study, or between the end of the Parent study and before enrollment into the extension study
- Any unresolved or irreversible toxicities during the Parent study that require permanent discontinuation of pertuzumab, according to Parent protocol or local label. Delay of treatment to wait for resolution of toxicities is allowed as long as it is within the guidelines of the respective Parent protocol and does not contradict exclusion criterion below.
- More than 9 weeks between the last dose of pertuzumab in the Parent study and the first dose pertuzumab in the extension study
- Left ventricular ejection fraction </= 50%
- Any serious uncontrolled concomitant disease that would contraindicate the use of pertuzumab or that would put the patient at high risk for treatment-related complications
- Treatment with any anti-cancer treatment (other than any treatment given as permitted in the Parent protocol) in the time period between last treatment in the Parent study and the first dose pertuzumab in the extension study (i.e. up to 9 weeks)
- Positive serum pregnancy test
- Women of child-bearing potential and men with partners of childbearing potential who do not agree to use a highly-effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the patient and/or partner for the duration of study treatment and for at least 7 months after the last dose of study medication. Male patients who do not agree to refrain from donating sperm during this same period. Male patients whose partner is pregnant who do not agree to use condoms for the duration of the pregnancy.
- Concurrent participation in any therapeutic clinical trial (other than the Parent study)
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol
Diese Seite fasst Informationen von öffentlichen Studienregister-Websites wie ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com usw. zusammen. Weitere Informationen zu dieser Studie finden Sie auf der Registerkarte „Für medizinische Fachkräfte" oder auf einer der Studienregister-Websites.
Die Informationen stammen direkt von Websites öffentlicher Register wie ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com usw. und wurden nicht modifiziert.
Results Disclaimer
Entdecken Sie ähnliche Studien
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
Teilen Sie Informationen über diese klinische Studie
Link to Pagedurch eine der folgenden Optionen
In die Zwischenablage kopiert